by Jason Heaviland | Apr 15, 2026
This study presents an integrated proteomics and metabolomics analysis of Alzheimer’s disease using serum samples. Across 11,000+ molecular features, Panome Bio identified systemic metabolic dysregulation, lipid transport disruption, and protein-level changes...
by Jason Heaviland | Mar 31, 2026
Metabolomics Comparison: A Head-to-Head Study Panome Bio conducted a controlled head-to-head metabolomics study using identical samples analyzed by a legacy library-based platform and Next-Generation Metabolomics®️. The results show a nearly 4× increase in detected...
by Jason Heaviland | Mar 25, 2026
Pinpointing the Pervasive: Exposomics Analysis of Alzheimer’s Disease This poster presents a comprehensive exposomics analysis of Alzheimer’s disease, leveraging both targeted and discovery workflows to characterize environmental exposures and their biological impact....
by Jason Heaviland | Mar 2, 2026
Exposomics Measuring Chemical Drivers of Human Disease Panome Bio’s Exposomics platform enables comprehensive measurement of chemical exposures that drive human disease. Using integrated discovery (32,000+ compounds) and targeted profiling (235 priority chemicals), we...
by Jason Heaviland | Feb 26, 2026
Our partners at Indiana University leveraged Next-Generation Metabolomics to profile metabolic and lipidomic changes in gingival crevicular fluid from healthy individuals and patients with periodontitis. Using dual LC-MS platforms and deep-learning–assisted data...
